GlassScriptPhysician profile
Arica L Sargent
NPI 1538219621
$10,241.45
in general payments reported to CMS, 2019-2025
29 companies · $2,531 in 2025
The $2,531 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,135 · 2022: $1,448 · 2023: $1,802 · 2024: $2,325 · 2025: $2,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,658.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,412.43 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $992.86 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $836.04 | 2021-2025 | Ajovy, Austedo Xr |
| Currax Pharmaceuticals LLC | $833.49 | 2021-2024 | Onzetra Xsail, Contrave |
| Tonix Medicines, INC. | $794.72 | 2024-2025 | Zembrace Symtouch |
| Scilex Pharmaceuticals INC. | $655.36 | 2024-2025 | |
| Amgen INC. | $615.79 | 2021-2024 | Aimovig |
| Pfizer INC. | $439.21 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $403.99 | 2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $384.77 | 2022 | |
| Lilly USA, LLC | $382.01 | 2021-2025 | Reyvow, Emgality, Zepbound |
| Lundbeck LLC | $294.79 | 2021-2025 | Vyepti |
| Axsome Therapeutics, INC. | $229.95 | 2025 | Symbravo |
| Upsher-Smith Laboratories LLC | $213.63 | 2021-2023 | |
| Ucb, INC. | $137.77 | 2023-2025 | Nayzilam, Briviact |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $95.26 | 2021 | |
| Eisai INC. | $91.66 | 2024-2025 | |
| Impel Pharmaceuticals LLC | $77.02 | 2024-2025 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $76.54 | 2023-2024 | Eprontia, Zonisade |
| Ibsa Pharma INC. | $66.56 | 2024-2025 | Tirosint, Licart, Flector |
| Amneal Pharmaceuticals LLC | $45.37 | 2024-2025 | Brekiya, Avastin |
| Averitas Pharma INC. | $40.63 | 2025 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $28.12 | 2023 | Firdapse |
| Novo Nordisk INC | $22.61 | 2023 | Wegovy |
| Allergan, INC. | $22.12 | 2022 | |
| Novocure INC. | $19.49 | 2023 | Optune |
| Arbor Pharmaceuticals, INC. | $14.73 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.12 | 2021 | |
| Ge Healthcare | $3.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arica Sargent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.